1.Current status and progress of male breast cancer diagnosis and treatment
Journal of International Oncology 2012;39(9):686-689
Male breast cancer is rare,it mainly caused by the interaction of the genetic factors,hormone levels,way of life,and the environment.Its clinical manifestations are indolent tumors.The diagnosis method includes clinical medical examination and imaging examination,and pathology examination.The treatment is in reference to the female breast cancer treatment model,including surgery,chemoradiotherapy and endocrine therapy.Tumor size and axillary lymph nodes involvement are independent predictors of overall survival.
2.New targets on molecular target therapy of triple negative breast cancer
International Journal of Surgery 2014;41(11):766-769
Triple negative breast cancer (TNBC) is characterized by lack of expression of the estrogen (ER)and progesterone receptors (PRs) and the human epidermal growth factor receptor (HER-2) that are commonly observed in other breast cancer subtypes.Treatment options are limited since the hormonal receptor and HER-2 antagonists are ineffective for TNBC.In contrast to non-TNBC,TNBC is more aggressive with higher recurrence,metastatic,and mortality rates.Besides further studies on cytotoxic drugs and chemotherapy regimens,More studies on potential targeted molecular treatment of TNBC should be strengthened.For the moment,potential targeted molecular treatment of TNBC including antiangiogenic agents,epidermal growth factor receptor (EGFR) inhibitors and poly (adenosine diphosphate ribose) polymerase (PARP).In contrast to their surprising anti-tumor effectivness in basic experiments,these targeted molecular agents show no promising results in clinical trials by now.This article aims to review advancements of targeted molecular treatment of TNBC in recent years.
3.Clinical observation of docetaxel combined with S-1 in treatment of anthracycline-resistant TNBC
Wanli YE ; Jianfang WANG ; Hongjian YANG
Chinese Journal of Biochemical Pharmaceutics 2014;(3):116-118
Objective To observe and analyze the clinical efficacy of docetaxel and S-1 in treatment of anthracycline-resistant triple-negtive breast cancer(TNBC).Methods 64 cases with TNBC admitted in People' Hospital of Shaoxing City from June 2009 to June 2011were selected as research object.The clinical data of these cases were analyzed retrospectively.Anthracycline had been used to treat the cases, but with no effect or recurrence.Then docetaxel combined with S-1 was applied to the cases.Clinical efficacy and adverse reactions of the chemotherapy were observed and analyzed. Results After treatment,the efficiency of 64 cases was 54.69%,and the disease control rate was 79.69%.During the treatment,the main adverse reactions were gastrointestinal reactions and bone marrow suppression,without death,and patients could tolerate the adverse event.Follow-up results showed that the median time of progression was 10.5 months.After two years,progression-free survival rate was 0.Conclusion Docetaxel combined with S-1 has good clinical efficacy for anthracycline-resistant triple-negtive breast cancer,with relatively mild side effects,which may be an ideal adjuvant chemotherapy method.
4.Clinical analysis of 48 patients with metachronous bilateral primary breast cancer
Xiaoliang WANG ; Hongjian YANG ; Jun WANG
Chinese Journal of Primary Medicine and Pharmacy 2011;18(4):455-456
ObjectiveTo evaluate the characteristics,treatment and prognosis of metachronous bilateral primary breast cancer(mBPBC). MethodsClinical materials of 48 patients were performed with retrospective study. ResultsIn 48 patients,43 cases taken both sides modified radical mastectomy and 5 cases taken lumpectomy and axillary dissection in the second side.All patients were treated with chemical treatment and treated with radiotherapy in accordance with lymph node metastasis.Besides a part of patients were treated with endocrine therapy in accordance with the expression of estrogen receptor(ER)and progesterone receptor(PR).The follow-up time was 6 ~ 48 months and the average time was 21.9 months.No died and 5 cases found distant metastasis. ConclusionmBPBC should be diagnosed earlier,taken appropriate treatment and followed up actively,so it would have a better therapeutic effect.
5.Laparoscopic Treatment of Mammary Multiple Fibroadenoma
Daobao CHEN ; Hongjian YANG ; Shangnao XIE
Chinese Journal of Minimally Invasive Surgery 2001;0(03):-
Objective To investigate the feasibility of laparoscopic extirpation for mammary multiple fibroadenoma. Methods A total of 12 patients with multiple fibroadenoma that were diagnosed by ultrasonography and fine needle aspiration were enrolled in this study. Through an axillary small incision, the air was inflated into the retromammary space, which had been obtusely separated to build a surgical space. Then, 58 fibroadenomas were resected under a laparoscope. Frozen-section examination was carried out during the operation. Results All the masses of the 12 patients were laparoscopically extirpated successfully, without operative complications. The operation time was 40-150 minutes with a mean of 80 minutes. One month after the operation, the shape of the breast looked well and the sensation of the nipple remained normal. During a 1- to 36-month follow-up (mean 18.5 months), none of the patients had scars on the breast or tumor recurrence. All of them were satisfied with the cosmetic results. Conclusion Laparoscopic extirpation of mammary multiple fibroadenoma through the retromammary space is safe and feasible.
6.miRNA in breast cancer
Ping Lü ; Jiangliu YU ; Hongjian YANG ; Zhiqiang LING
Journal of International Oncology 2012;(12):921-924
The studies have shown that the genesis and development process of breast cancer is closely related with microRNAs (miRNAs).Multiple miRNAs are involved in the progress of the incidence of breast cancer,and can be used to assess the prognosis,clinical treatment of breast cancer,and to explore the resistance mechanisms.
7.Study on expression of TPS, VEGF of beast cancer patients and relationship with clinical pathological
Daobao CHEN ; Hongjian YANG ; Bo CHEN ; Xingfei YU ; Weiliang FENG
Chinese Journal of Biochemical Pharmaceutics 2015;37(5):121-123
Objective To investigate expression of TPS, VEGF of beast cancer patients and relationship with clinical pathological.Methods 68 cases of breast cancer were selected as experiment group, 36 cases with breast fibroma were selected as control group.TPS and VEGF were detected by elisa of patients before and after treatment.Serum TPS and VEGF levels and TNM staging were compared after operation.Results TPS and VEGF of the experiment group were higher than control group(P<0.05).TPS and VEGF of experiment group after operation were higher than before operation.TPS and VEGF increased with the grade of tumor, but there was no significance between grade Ⅰ and 0.The expression of VEGF in tumor diameter≤2 cm group was significantly lower than >2 cm group(P<0.05).TPS and VEGF of axillary lymph node metastasis group and axillary lymph node metastasis had significant difference(P<0.05).The concentration of TPS was significantly higher than that of estrogen and progesteronepositive group in estrogen receptor negative, progesterone receptor negative (P<0.05).Conclusion TPS, VEGF levels in the serum of breast cancer patients showed high expression, the expression of TPS, VEGF levels related to axillary lymph node metastasis, estrogen receptor, progesterone receptor.
8.Study on effect of anthracyclines on VEGF-C, VEGFR-3, ER and E-cadherin in serum of patients with breast cancer
Daobao CHEN ; Bo CHEN ; Hongjian YANG ; Xingfei YU ; Weiliang FENG
Chinese Journal of Biochemical Pharmaceutics 2015;(6):137-139
Objective To investigate effect of anthracyclines of VEGF-C, VEGFR-3, ER and E-cadherin in serum of patients with breast cancer.Methods 43 patients with breast cancer were selected and randomly divided into experimental group and control group, 40 cases in each group.According to the experimental program based on the treatment, serum VEGF-C, VEGFR-3 levels and breast tissue ER and E-cadherin were detected after the end of the treatment.Results Compared with the control group, VEGF-C, VEGFR-3 levels of the experiment group were lower( P<0.05),ER level was lower(P<0.05) and E-cadherin level was higher(P<0.05).Conclusion the ER, VEGFR-3 and VEGF-C levels in breast cancer patients can significantly decrease the E-cadherin level, and it has a guiding significance for clinical.
9.Relationship Between Tongue Manifestations and Immune Function in Chronic Hepatitis B with HBsAg, HBeAg and HBcAb Positive
Xiaoyan ZHOU ; Hanlin ZHONG ; Huixian WEN ; Futai YANG ; Hongjian LIU
Journal of Guangzhou University of Traditional Chinese Medicine 2001;0(01):-
[ Objective ] To investigate the relationship between tongue manifestations and immune function in chronic hepatitis B with HBsAg, HBeAg and HBcAb positive. [Methods] Among the cases of HBsAg, HBeAg and HBcAb positive from the out - patient department and health screening survey, 200 chronic hepatitis patients and 100 asymptomatic HBV carriers with glumatic - pyruvic transaminase at normal level were included. Thirty healthy volunteers served as control. Relationship of tongue manifestations with phytohemagglutinin (PHA) skin test and the serum levels of immunoglobulin (Ig) G, IgA and IgM was analyzed. [Results] With the development of chronic hepatitis, the immune function became disordered and tongue manifestations abnormal. Reddish tongue with or without yellowish greasy fur or yellowish fur showed the hyperactivity of immune function; whitish swollen tongue with or without whitish greasy fur indicated the hypoactivity of immune function; dull purplish tongue was the sign of disordered immune function. The shape and color of tongue was superior to tongue fur in showing the condition of immune function ( P
10.A randomized controlled research on treating early breast cancer with axillary lymph node group dissec-tion oriented by sentinel lymph nodes instead of axillary dissection
Xingfei YU ; Xiaodan PAN ; Daobao CHEN ; Weiliang FENG ; Hongjian YANG
Journal of Endocrine Surgery 2015;(2):101-105
Objective To research the impact of axillary limph node group dissection oriented by senti-nel lymph nodes instead of axillary dissection on upper limb lymph edema and disease -free survival ( DFS ).Methods We designed a randomized controlled research , which included 205 cases of operatable breast cancer (AJCC 7th:stage I or stage IIa)from Jan.2011 to Jan.2013.Those cases were separated into 2 groups randomly ( random number method ):group A underwent mastectomy ( or lumpectomy ) and axillary group lymphadenectomy oriented by sentinel lymph node biopsy ( SLNB) ( if positive continued for ALND ) while group B underwent mastec-tomy(or lumpectomy)and axillary lymph node dissection(ALND).All patients underwent SLNB by blue dye method and received adjuvant therapy after surgery according to National Comprehensive Cancer Network ( NCCN) guideline and Chinese anti-cancer association guideline .Results There were 101 cases in group A and 104 ca-ses in group B , but 1 case in group A was excluded for false negative of SLN.The midium follow-up was 30 months.There were no significant differences of average age , tumor size, grade, estrogen receptor (ER),proges-terone receptor ( PR) and human epidermal growth factor receptor 2 ( HER2 ) expression between the 2 groups. Group A had a lower frequency of lymph edema than group B (4.0%vs 17.3%,χ2 =9.384,P=0.002), and al-so a milder degree ( mild 2%vs 11.5%,middle 2%vs 3.8%,severe 0%vs 1.9%).There were no significant differences of upper limb sensory disorder (14.0%vs 16.3%,χ2 =0.218,P=0.641), neither of DFS(Log-Rank analysis:3-year average DFS 32.89 months vs 33.72 months,χ2 =0.186,P=0.667;Cox risk model analysis:HR=1.395,P=0.495)between the 2 groups.Conclusion Axillary group lymphadenectomy oriented by SLNB can reduce the happening of lymph edema from ALND and has a comparative effect on DFS as ALND .